The company is dedicated to developing precision medicines that target protein myristoylation, with a primary focus on oncology but also exploring potential applications across other diseases. By offering novel proprietary inhibitors of human N-myristoyl transferase (NMT), Myricx Pharma aims to enable patients to receive effective treatment for a wide range of diseases including cancer and viral infections. The company's inhibitors result in specific cancer cell killing, making them a promising candidate for precision medicine.